Pelosi Dives into AI Meds: Congress Betting on Your Health Data?
Nancy Pelosi (D-CA) and her husband Paul continue to draw attention with timely investments in high-growth sectors. On March 15, 2026, Paul Pelosi purchased 1,000 shares of Tempus AI (NASDAQ: TEM), a health technology company leveraging artificial intelligence for precision medicine. The transaction, valued between $50,001 and $100,000, was disclosed on March 30, 2026, per congressional filing requirements.
Tempus AI specializes in genomic testing, clinical data analysis, and AI-driven diagnostics, particularly in oncology. The company has secured multiple FDA approvals for its next-generation sequencing tests, including the xT CDx 648-gene panel for solid tumors. These regulatory wins have fueled investor optimism, with TEM shares rising approximately 12% since the Pelosi trade amid positive momentum around FDA pathways and precision medicine advancements.
This latest move fits a pattern of Pelosi family interest in AI and healthcare technology. Tempus, founded in 2015, builds one of the world’s largest libraries of clinical and molecular data to help physicians deliver personalized treatments. As Congress debates healthcare policy, AI regulation, and data privacy, critics question whether such investments create the appearance of potential conflicts — even as supporters note the trades comply with STOCK Act disclosure rules.
Why This Trade Matters
Tempus AI operates at the intersection of two exploding fields: artificial intelligence and precision medicine. With ongoing FDA clearances and ambitions to expand approved testing volumes, the company positions itself as a leader in using AI to analyze vast patient datasets for better diagnostics and drug development. The stock’s performance reflects broader market enthusiasm for AI-healthcare plays.
Under current law, members of Congress and their spouses must disclose transactions over $1,000 within 45 days. The Pelosi filing meets this timeline. However, repeated high-profile trades by congressional families keep the spotlight on reform proposals, including outright bans on individual stock trading by lawmakers and spouses.
Nancy Pelosi, a longtime leader in Democratic politics and former Speaker of the House, has faced scrutiny over her family’s investment portfolio for years. This Tempus AI position adds to discussions about congressional access to market-moving information in sectors like healthcare and technology, where legislation can significantly impact stock values.
As of early May 2026, the trade appears well-timed given Tempus’ regulatory tailwinds and sector growth. Whether it reflects savvy investing or raises broader ethical questions about transparency remains a topic of debate in Washington and among watchdog groups.
CongressionalIntel will continue monitoring these filings for patterns in AI, healthcare, and other key industries. For investors and voters alike, Pelosi’s latest healthcare AI bet highlights the growing overlap between Capitol Hill decisions and cutting-edge technology markets.